Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study
Open accessAbstract
Summary This prospective study, in the very early phase after initiation of glucocorticoid (GC) treatment, showed that alendronate was effective in suppressing accelerated bone resorption and subsequent decrease in bone mineral density (BMD) at the lumbar spine of patients with high-dose GC treatment.Introduction How bisphosphonates affect bone metabolism and BMD of patients with high-dose GC in the early phase, especially within 1 month is unclear.Methods We examined the prospective effects of daily 5 mg alendronate on bone metabolism and BMD in 20 patients with high-dose GC (at least 40 mg prednisolone/day) and compared them to 34 high-dose GC-treated patients without alendronate.Results Serum levels of calcium decreased at day 28 in the alendronate group. Urinary calcium excretion significantly increased after day 7 in both groups. The increase in serum parathyroid hormone (PTH) level at day 7 in the control group was not observed in the alendronate group, but PTH levels increased at day 28 and month 3 in the alendronate group. As for the bone turnover markers, the serum osteocalcin level decreased in both alendronate and control groups, but serum bone-type alkaline phosphatase levels did not show significant changes. Although the urinary type I collagen cross-linked N-telopeptide (NTX) level showed significant increases on days 7 and 28 in the control group; such early increases in urinary NTX were not observed in the alendronate group. Thereafter, the urinary NTX levels fell slowly in the alendronate group significantly. BMD at the lumbar spine significantly decreased from month 1 in the control group, whereas in the alendronate group, BMD at the lumbar spine maintained almost the same level at all time points observed.Conclusion Alendronate was effective in suppressing bone resorption and subsequent BMD decrease at the lumbar spine in patients with high-dose GC treatment.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In clinical practice, both bisphosphonates and PTH increase spine BMD to a greater extent than hip BMD.
“In clinical practice, both bisphosphonates and PTH increase the spine BMD to a greater extent than the hip BMD [12, 14, 47, 50-53].”
From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276 · see citing works
Use of Inhaled Corticosteroids and Risk of Fractures
van Staa, T. P., Leufkens, H. G. M., & Cooper, C. C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.581 · Cited by 1,297 · see citing works
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294 · see citing works
Use of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263 · see citing works
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258 · see citing works
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
CANALIS, E. M., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0394-0 · Cited by 1,118 · see citing works
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839 · see citing works
Van Staa, T. P., Laan, R. F., Barton, I. P., Cohen, S., Reid, D. M., & Cooper, C. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11283 · Cited by 559 · see citing works
Blackburn, G. F., Shah, H. P., Kenten, J. H., Leland, J. K., Kamin, R. A., Link, J., Peterman, J., Powell, M. J., Shah, A., & Talley, D. B. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.9.1534 · Cited by 558 · see citing works
II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women
Cranney, A., Wells, G., Willan, A. R., Griffith, L. E., Zytaruk, N. L., Robinson, V. A., Black, D. M., Adachi, J. D., Shea, B., Tugwell, P., et al. (2002) · Endocrine Reviews · doi:10.1210/er.2001-2002 · Cited by 444 · see citing works
Glucocorticoid-induced osteoporosis: an update
Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E., & Giustina, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.009 · Cited by 362 · see citing works
Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum
Gomez, B., Ardakani, S., Ju, J., Jenkins, D. K., Cerelli, M. J., Daniloff, G. Y., & Kung, V. T. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.11.1560 · Cited by 311 · see citing works
Does a Fracture at One Site Predict Later Fractures at Other Sites? A British Cohort Study
van Staa, T. P., van Staa, T. P., van Staa, T. P., Leufkens, H. G. M., & Cooper, C. C. (2002) · Osteoporosis International · doi:10.1007/s001980200084 · Cited by 292 · see citing works
VI. Meta-Analysis of Calcitonin for the Treatment of Postmenopausal Osteoporosis
Cranney, A., Tugwell, P., Zytaruk, N. L., Robinson, V. A., Weaver, B., Shea, B., Wells, G., Adachi, J. D., Waldegger, L., Guyatt, G. H., et al. (2002) · Endocrine Reviews · doi:10.1210/er.2001-6002 · Cited by 286 · see citing works
III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis
Cranney, A., Tugwell, P., Adachi, J. D., Weaver, B., Zytaruk, N. L., Παπαϊωάννου, Α., Robinson, V. A., Shea, B., Wells, G., & Guyatt, G. H. (2002) · Endocrine Reviews · doi:10.1210/er.2001-3002 · Cited by 281 · see citing works
Suzuki, Y., Nawata, H., Soen, S., Fujiwara, S., Nakayama, H., Tanaka, I., Ozono, K., Sagawa, A., Takayanagi, R., Tanaka, H., et al. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0586-6 · Cited by 281 · see citing works
Oral glucocorticoid use is associated with an increased risk of fracture
Steinbuch, M., Youket, T. E., & Cohen, S. B. (2004) · Osteoporosis International · doi:10.1007/s00198-003-1548-3 · Cited by 280 · see citing works
Alendronate or Alfacalcidol in Glucocorticoid-Induced Osteoporosis
de Nijs, R. N. J., Jacobs, J. W. G., Lems, W. F., Laan, R., Algra, A., Huisman, A.-M., Buskens, E., Laet, C. E. D. H. D., Oostveen, A. C. M., Geusens, P., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053569 · Cited by 207 · see citing works
Corticosteroid effects on proximal femur bone loss
Sambrook, P. N., Birmingham, J., Kempler, S., Kelly, P., Eberl, S., POCOCK, N. A., Yeates, M. G., & Eisman, J. A. (1990) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650051204 · Cited by 186 · see citing works
Woitge, H. W., Pecherstorfer, M., Li, Y., Keck, A. V., Horn, E., Ziegler, R., & Seibel, M. J. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.5.792 · Cited by 181 · see citing works
Nawata, H., Soen, S., Takayanagi, R., Tanaka, I., Takaoka, K., Fukunaga, M., Matsumoto, T., Suzuki, Y., Tanaka, H., Fujiwara, S., et al. (2005) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-004-0596-x · Cited by 145 · see citing works
Alendronate in the Treatment of Primary Hyperparathyroid-Related Osteoporosis: A 2-Year Study
Parker, C. R., Blackwell, P. J., Fairbairn, K. J., & Hosking, D. J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-010385 · Cited by 128 · see citing works
Amin, S., LaValley, M. P., Simms, R. W., & Felson, D. T. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.8.1512 · Cited by 124 · see citing works
Effect of Alendronate on the Age-Specific Incidence of Symptomatic Osteoporotic Fractures
Hochberg, M. C., Thompson, D. E., Black, D. M., Quandt, S. A., Cauley, J. A., Geusens, P., Ross, P. D., & Baran, D. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050104 · Cited by 100 · see citing works
Kaji, H., Sugimoto, T., Kanatani, M., Nishiyama, K., & Chihara, K. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.5.734 · Cited by 85 · see citing works
Self-citationOkada, Y., Nawata, M., Nakayamada, S., Saito, K., & Tanaka, Y. (2008) · The Journal of Rheumatology · doi:10.3899/jrheum.080168 · Cited by 60 · see citing works
Haugeberg, G., Griffiths, B., Sokoll, K. B., & Emery, P. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.011734 · Cited by 58 · see citing works
Alendronate for osteoporosis in men with androgen-repleted hypogonadism
Shimon, I., Eshed, V., Doolman, R., Sela, B., Karasik, A., & Vered, I. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1879-3 · Cited by 37 · see citing works
Alendronate or Alfacalcidol in Glucocorticoid-Induced Osteoporosis
de Nijs, R. N. J., Jacobs, J. W. G., Lems, W. F., Laan, R., Algra, A., Huisman, A.-M., Buskens, E., Laet, C. E. D. H. D., Oostveen, A. C. M., Geusens, P., et al. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000251010.34115.0a · Cited by 34 · see citing works
Jacobs, J. W. G., de Nijs, R. N. J., Lems, W. F., Geusens, P., Laan, R., Huisman, A.-M., Algra, A., Buskens, E., Hofbauer, L. C., Oostveen, A. C. M., et al. (2007) · PubMed · Cited by 34 · see citing works
Dexamethasone suppresses Smad3 pathway in osteoblastic cells
Iu, M.-F., Kaji, H., Sowa, H., Naito, J., Sugimoto, T., & Chihara, K. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.05962 · Cited by 34 · see citing works
Self-citationMok, C. C., Tong, M. K. H., To, C. H., Siu, Y.-P., & M., K. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0505-y · Cited by 32 · see citing works
Kuroki, Y., Kaji, H., Kawano, S., Kanda, F., Takai, Y., Kajikawa, M., & Sugimoto, T. (2008) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-007-0821-5 · Cited by 29 · see citing works
Self-citationGlucocorticoid Excess Affects Cortical Bone Geometry in Premenopausal, but not Postmenopausal, Women
Kaji, H., Yamauchi, M., Chihara, K., & Sugimoto, T. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9106-9 · Cited by 18 · see citing works
Self-citationKaji, H., Hisa, I., Inoue, Y., Naito, J., Sugimoto, T., & Kasuga, M. (2008) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-008-0005-y · Cited by 17 · see citing works
Self-citationKaji, H., Yamauchi, M., Chihara, K., & Sugimoto, T. (2008) · Hormone and Metabolic Research · doi:10.1055/s-2007-993170 · Cited by 8 · see citing works
Self-citationWarrington (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200101)44:1 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Yao, W., Dai, W., Jiang, L., Lay, E. Y.-A., Zhong, Z. A., Ritchie, R. O., Li, X., Ke, H. Z., & Lane, N. E. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3308-6 · Cited by 116 · see citing works
Gifre, L., Ruiz-Gaspà, S., Monegal, A., Nomdedeu, B., Filella, X., Guañabens, N., & Peris, P. (2013) · Bone · doi:10.1016/j.bone.2013.08.016 · Cited by 95 · see citing works
Martiniaková, M., Bíro, R., Kováčová, V., Babikova, M., Zemanová, N., Mondočková, V., & Omelka, R. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02418-8 · Cited by 79 · see citing works
Cavalier, E., Bergmann, P., Bruyère, O., Delanaye, P., Durnez, A., Devogelaer, J.-P., Ferrari, S. L., Gielen, E., Goemaere, S., Kaufman, J.-M., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3561-3 · Cited by 63 · see citing works
Rossi, M., Battafarano, G., Pepe, J., Minisola, S., & Fattore, A. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184502 · Cited by 44 · see citing works
Prevention of glucocorticoid induced bone changes with beta-ecdysone
Dai, W., Jiang, L., Lay, Y.-A. E., Chen, H., Jin, G., Zhang, H., Kot, A., Ritchie, R. O., Lane, N. E., & Yao, W. (2015) · Bone · doi:10.1016/j.bone.2015.01.001 · Cited by 30 · see citing works
Role of Parathyroid Hormone in Bone Fragility of Postmenopausal Women with Vitamin D Insufficiency
Yamauchi, M., Kaji, H., Nawata, K., Takaoka, S., Yamaguchi, T., & Sugimoto, T. (2011) · Calcified Tissue International · doi:10.1007/s00223-011-9464-6 · Cited by 29 · see citing works
Self-citationKenanidis, E. I., Potoupnis, M. E., Kakoulidis, P., Leonidou, A. O., Sakellariou, G. T., Sayegh, F. E., & Tsiridis, E. E. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1040387 · Cited by 20 · see citing works
Shikano, K., Kaneko, K., Kawazoe, M., Kaburaki, M., Hasunuma, T., & Kawai, S. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.6230 · Cited by 9 · see citing works
Hishida, E., Masuda, T., Akimoto, T., Sato, R., Wakabayashi, N., Miki, A., Otani, N., Imai, T., Sugase, T., Takeda, S., et al. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.6194 · Cited by 5 · see citing works
Bone Turnover Markers and Glucocorticoid Treatments
Devogelaer, J., Durnez, A., Gruson, D., & Manicourt, D. H. (2017) · Biomarkers in disease · doi:10.1007/978-94-007-7693-7_23 · Cited by 4 · see citing works
Sato, R., Akimoto, T., Imai, T., Nakagawa, S., Okada, M., Miki, A., Takeda, S., Yamamoto, H., Saitô, O., Muto, S., et al. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.7180 · Cited by 3 · see citing works
Biochemical bone markers and biological effects of osteoporosis therapy
Kovačev-Zavišić, B., Novaković-Paro, J., Djuric, N., Ičin, T., Todorovic-Djilas, L., & Kovacev, N. (2012) · Vojnosanitetski pregled · doi:10.2298/vsp1205432k · Cited by 2 · see citing works
Ikeda, T., Maruyama, K., Kaji, H., & Akagi, M. (2013) · Modern Rheumatology · doi:10.3109/14397595.2013.860886 · Cited by 1 · see citing works
Self-citationBone Turnover Markers and Glucocorticoid Treatments
Devogelaer, J., Durnez, A., Gruson, D., & Manicourt, D. H. (2015) · Exposure and Health · doi:10.1007/978-94-007-7745-3_23-1 · Cited by 1 · see citing works
(2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32834decbe
- Authors
- Kaji, H., Kuroki, Y., Murakawa, Y., Funakawa, I., Funasaka, Y., Kanda, F., & Sugimoto, T.
- Affiliations
- Kobe University (JP)
- Shimane University (JP)
- Hyogo Chuo National Hospital (JP)
- Corresponding author
- Kaji, H.
- Venue
- Osteoporosis International
- Published
- 2009-11-17
- Volume
- 21
- Issue
- 9
- Pages
- 1565-1571
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2005610976
- Cited by
- 16
- References
- 38
- Citations by year
- 2024: 1 · 2019: 1 · 2017: 1 · 2016: 4 · 2015: 4 · 2013: 2 · 2012: 1
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Kobe University Repository Kernel (Kobe University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- alendronate, bisphosphonates, glucocorticoid-induced osteoporosis, high-dose glucocorticoids, bone mineral density, bone resorption, bone turnover markers, parathyroid hormone, osteocalcin, urinary N-telopeptide, lumbar spine, serum calcium, prednisolone
- MeSH terms
- Adult, Aged, Bone Resorption, Calcium, Drug Administration Schedule, Female, Glucocorticoids, Humans, Lumbar Vertebrae, Male, Middle Aged, Osteoporosis, Parathyroid Hormone, Prednisolone, Prospective Studies, Biomarkers, Bone Density, Treatment Outcome, Alendronate, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
